This bill matters because it directly addresses disparities in access to advanced cancer care. Lung cancer biomarker testing helps doctors understand the unique genetic makeup of a person's tumor, allowing them to recommend highly targeted treatments that are often more effective and have fewer side effects than traditional chemotherapy.

Without a federal requirement, coverage for this type of testing can vary from state to state or may not be available at all through some Medicaid plans. If this bill becomes law, all Medicaid beneficiaries with lung cancer will have access to this modern diagnostic tool, potentially leading to better health outcomes and a more personalized approach to their cancer treatment. If it doesn't become law, access to these critical tests would continue to depend on individual state Medicaid policies, potentially leaving some patients without coverage.